Chemotherapie ± Androgenrezeptorantagonisten beim metastasierten hormonsensitiven Prostatakarzinom

BACKGROUND: Although androgen deprivation therapy (ADT) alone has been the standard of care (SOC) in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) for decades, combination therapies of novel hormone therapy (androgen receptor-targeting agents [ARTA]) or docetaxel chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Wenzel, Mike, Hoeh, Benedikt, Chun, Felix K. H., Mandel, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2023
Materias:
Leitthema
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073052/
https://www.ncbi.nlm.nih.gov/pubmed/36763112
http://dx.doi.org/10.1007/s00120-023-02029-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073052/
https://www.ncbi.nlm.nih.gov/pubmed/36763112
http://dx.doi.org/10.1007/s00120-023-02029-0

Ejemplares similares